This phase I clinical trial studies how well magnetic resonance (MR) imaging works in detecting pulmonary function in patients receiving chest (thoracic) radiation therapy. Comparing results of diagnostic procedures done before, during, and after radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02478255.
PRIMARY OBJECTIVES:
I. To evaluate dose- and time–dependence of radiation therapy (RT)-induced changes in magnetic resonance imaging (MRI)-defined local function/structure.
SECONDARY OBJECTIVES:
I. Test whether particular imaging features at baseline can predict the degree of radiation-induced lung injury that will develop.
OUTLINE:
Patients receive 129-Xenon (Xe) gas via inhalation and then undergo MR spectroscopic imaging scan, ventilation MRI, and gas exchange MRI. Patients then undergo a free-breathing ultra-short-echo time MRI. Patients then receive gadoteridol or gadobutrol intravenously (IV) and undergo breath-hold perfusion magnetic resonance imaging at baseline (before radiation therapy begins), at 6-12 weeks after radiation therapy, and 5-7 months after radiation therapy.
Lead OrganizationDuke University Medical Center
Principal InvestigatorJoseph G. Mammarappallil
